BAJAJ BROKING
Zydus Lifesciences has announced its consolidated financial results for the third quarter of FY24-25, reporting total revenue from operations of ₹5,269.1 million and a net profit of ₹1,023.5 crore. The company recorded a profit before tax (PBT) of ₹1,184.1 crore, with total expenses amounting to ₹4,142.5 crore. Key financial components include finance costs of ₹32 crore and other expenses of ₹1,534.2 crore. The pharmaceuticals segment contributed ₹4,809.9 crore in revenue, while the consumer products segment added ₹459.2 crore. These results underscore the company's strong financial performance and operational efficiency for the quarter.
Total Revenue from Operations: ₹5,269.1 crore, up 17% from last year.
Net Profit: ₹1,023.5 crore, up 30% over last year.
Profit Before Tax (PBT): ₹1,184.1 crore
Finance Costs: ₹32 crore
Other Expenses: ₹1,534.2 crore
Total Expenses: ₹4,142.5 crore
Segment Contribution:
Pharmaceuticals Revenue: ₹4,809.9 crore
Consumer Products Revenue: ₹459.2 crore
Zydus Lifesciences posted strong revenue growth in Q3 FY24-25, showcasing its resilience and strategic execution. The company’s total revenue stood at ₹5,269.1 crore, marking a notable increase compared to the previous year’s ₹4,505.2 crore.
The net profit for the quarter came in at ₹1,023.5 crore, reflecting solid bottom-line growth. The company’s cost management and operational efficiencies contributed to the overall profitability.
Revenue: ₹4,809.9 crore
Profit Before Tax: ₹1,175.3 crore
Steady growth across key product categories
Revenue: ₹459.2 crore
Profit Before Tax: ₹8.8 crore
Continued expansion in consumer health business
The pharmaceutical sector recorded total revenue from operations of ₹5,269.1 crore in Q3 FY24-25. Zydus Lifesciences reported a profit before tax (PBT) of ₹1,184.1 crore, with a net profit of ₹1,023.5 crore. The pharmaceuticals segment contributed ₹4,809.9 crore, while the consumer products segment accounted for ₹459.2 crore. The company's operational efficiencies and global sales have bolstered its financial performance this quarter.
Zydus Lifesciences, a global life sciences company engaged in the discovery, development, manufacturing, and marketing of a range of healthcare therapies, reported its financial results for the third quarter, outlining performance across its business segments. The company recorded contributions from both the pharmaceuticals and consumer products segments, with key financial metrics remaining in line with the previous quarter. As part of the Zydus Group, which employs over 27,000 people worldwide, the company continues its operations in healthcare solutions and maintains a presence in global markets.
Particulars | Q3 FY24-25 (₹ Crore) | Q2 FY24-25 (₹ Crore) | Q3 FY23-24 (₹ Crore) |
Revenue from Operations | 5,269.1 | 5,237 | 4,505.2 |
Profit Before Tax (PBT) | 1,184.1 | 1,270.9 | 925.5 |
Net Profit | 1,023.5 | 911.2 | 789.6 |
Total Expenses | 4,142.5 | 4,034.3 | 3,617.4 |
Depreciation and Amortisation | 229 | 233.6 | 194.8 |
Finance Costs | 32 | 25.1 | 19.8 |
Other Expenses | 1,534.2 | 1,470.4 | 1,137.6 |
Pharmaceuticals Revenue | 4,809.9 | 4,747.5 | 4,105.3 |
Consumer Products Revenue | 459.2 | 489.5 | 399.9 |
Source: Zydus Lifesciences' Financial Data submitted to BSE.
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Sun Pharma's $355M Acquisition & Syngene's $56M
11 Mar, 2025 | 4 Min. read
Stock Market Live Updates | 10 March 2025
10 Mar, 2025 | 10 Min. read
Oil Slumps and China Retaliates – Key Market Movers Today!
10 Mar, 2025 | 4 Min. read
Market Moves
10 Mar, 2025 | 3 Min. read
Stock Market Live Updates | 11 March 2025
10 Mar, 2025 | 9 Min. read
Stock Market Live Updates | 07 March 2025
07 Mar, 2025 | 8 Min. read
BEL’s Rs577-Cr Boost & Biocon’s U.S. Expansion
07 Mar, 2025 | 4 Min. read
Indian Equity Markets Show Resilience Despite Global Headwinds
07 Mar, 2025 | 2 Min. read
Markets on Fire
06 Mar, 2025 | 3 Min. read
Stock Market Live Updates | 06 March 2025
06 Mar, 2025 | 9 Min. read
Apollo’s ₹250 Cr Cancer Care Investment & Power Grid’s Big Transmission Wins
05 Mar, 2025 | 4 Min. read
Stock Market Live Updates | 05 March 2025
05 Mar, 2025 | 9 Min. read
What is GIFT Nifty?
17 Sep, 2024 | 4 Min. read
What is Put Call Ratio?
06 Jan, 2025 | 5 Min. read
What is Algorithmic Trading?
01 Aug, 2023 | 3 Min. read
Demat Account Meaning and Its Importance
19 Sep, 2024 | 4 Min. read
How to Open a Demat Account? A Step-by-Step Guide
29 Sep, 2022 | 4 Min. read
What Is The Meaning Of Margin Trading
22 Mar, 2024 | 4 Min. read
What is India VIX?
01 Dec, 2023 | 5 Min. read
How to Open Demat Account for Minors?
01 Aug, 2023 | 5 Min. read
What is Trading on Equity
01 Aug, 2023 | 5 Min. read
What is the Bond Market?
09 Sep, 2023 | 5 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading